141 related articles for article (PubMed ID: 21356574)
41. Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Iwase M; Yoshiba S; Uchid M; Takaoka S; Kurihara Y; Ito D; Hatori M; Shintani S
Int J Oncol; 2007 Nov; 31(5):1141-7. PubMed ID: 17912441
[TBL] [Abstract][Full Text] [Related]
42. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin.
Oda A; Katayose Y; Yabuuchi S; Yamamoto K; Mizuma M; Shirasou S; Onogawa T; Ohtsuka H; Yoshida H; Hayashi H; Rikiyama T; Kim H; Choe Y; Kim K; Son H; Motoi F; Egawa S; Unno M
Anticancer Res; 2009 Apr; 29(4):1201-9. PubMed ID: 19414365
[TBL] [Abstract][Full Text] [Related]
43. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
44. The p53 tumor suppressor gene in anticancer agent-induced apoptosis and chemosensitivity of human gastrointestinal cancer cell lines.
Yamamoto M; Maehara Y; Oda S; Ichiyoshi Y; Kusumoto T; Sugimachi K
Cancer Chemother Pharmacol; 1999; 43(1):43-9. PubMed ID: 9923540
[TBL] [Abstract][Full Text] [Related]
45. Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation.
Quattrini I; Conti A; Pazzaglia L; Novello C; Ferrari S; Picci P; Benassi MS
Oncol Rep; 2014 Jan; 31(1):370-5. PubMed ID: 24253938
[TBL] [Abstract][Full Text] [Related]
46. Analysis of protein phosphorylation in cisplatin-treated human cells following annexin V-based separation and multi-antibody screening.
O'Meara E; Cruet-Hennequart S; Carty MP
Cancer Genomics Proteomics; 2010; 7(5):279-86. PubMed ID: 20952762
[TBL] [Abstract][Full Text] [Related]
47. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
48. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
[TBL] [Abstract][Full Text] [Related]
49. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.
Stuhldreier F; Kassel S; Schumacher L; Wesselborg S; Proksch P; Fritz G
Cancer Lett; 2015 May; 361(1):39-48. PubMed ID: 25697484
[TBL] [Abstract][Full Text] [Related]
50. Lovastatin prevents cisplatin-induced activation of pro-apoptotic DNA damage response (DDR) of renal tubular epithelial cells.
Krüger K; Ziegler V; Hartmann C; Henninger C; Thomale J; Schupp N; Fritz G
Toxicol Appl Pharmacol; 2016 Feb; 292():103-14. PubMed ID: 26739623
[TBL] [Abstract][Full Text] [Related]
51. Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells.
Yuan JM; Li XD; Liu ZY; Hou GQ; Kang JH; Huang DY; Du SX
Asian Pac J Cancer Prev; 2011; 12(12):3465-9. PubMed ID: 22471498
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.
Vanas V; Haigl B; Stockhammer V; Sutterlüty-Fall H
PLoS One; 2016; 11(8):e0161023. PubMed ID: 27513462
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Paiva-Oliveira DI; Martins-Neves SR; Abrunhosa AJ; Fontes-Ribeiro C; Gomes CMF
Cancer Chemother Pharmacol; 2018 Jan; 81(1):49-63. PubMed ID: 29086064
[TBL] [Abstract][Full Text] [Related]
54. Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response.
Kiran S; Oddi V; Ramakrishna G
Exp Cell Res; 2015 Feb; 331(1):123-141. PubMed ID: 25445786
[TBL] [Abstract][Full Text] [Related]
55. Lovastatin protects keratinocytes from DNA damage-related pro-apoptotic stress responses stimulated by anticancer therapeutics.
Ziegler V; Albers A; Fritz G
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1082-92. PubMed ID: 26876155
[TBL] [Abstract][Full Text] [Related]
56. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Tsuchiya H
BMC Cancer; 2019 Jul; 19(1):689. PubMed ID: 31307409
[TBL] [Abstract][Full Text] [Related]
57. Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells.
Siddiqui RA; Harvey KA; Xu Z; Natarajan SK; Davisson VJ
Bioorg Med Chem; 2014 Mar; 22(6):1899-908. PubMed ID: 24556504
[TBL] [Abstract][Full Text] [Related]
58. Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.
Morgado-Palacin L; Llanos S; Urbano-Cuadrado M; Blanco-Aparicio C; Megias D; Pastor J; Serrano M
Carcinogenesis; 2014 Dec; 35(12):2822-30. PubMed ID: 25344835
[TBL] [Abstract][Full Text] [Related]
59. In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity.
Gatti M; Solari A; Pattarozzi A; Campanella C; Thellung S; Maniscalco L; De Maria R; Würth R; Corsaro A; Bajetto A; Ratto A; Ferrari A; Daga A; Barbieri F; Florio T
Exp Cell Res; 2018 Feb; 363(1):48-64. PubMed ID: 29305964
[TBL] [Abstract][Full Text] [Related]
60. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
Thurnher M; Nussbaumer O; Gruenbacher G
Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
